Skip to main content
JAK inhibitors in GCA?

We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELE

Dr. John Cush RheumNow

1 year 8 months ago
JAK inhibitors in GCA? We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg
Highlights in axSpA

Dr. Marina Magrey discusses highlights in axSpA from the first day at #ACR24

https://t.co/LvvmzlXW

Dr. John Cush RheumNow

1 year 8 months ago
Highlights in axSpA Dr. Marina Magrey discusses highlights in axSpA from the first day at #ACR24 https://t.co/LvvmzlXWw7 https://t.co/thf9MiMo32
RA Treatment Adherence: Is decision making really shared?

Dr. Jonathan Kay interviews Dr. Cécile Gaujoux-Viala about a

Dr. John Cush RheumNow

1 year 8 months ago
RA Treatment Adherence: Is decision making really shared? Dr. Jonathan Kay interviews Dr. Cécile Gaujoux-Viala about abstract 0360 at #ACR24. https://t.co/KwXHutfQko https://t.co/bCVM3JrFEz
Treat-to-Target Improves Fertility in Women with RA

Dr. Richard Conway discusses abstract 1647, presented at #ACR24

ht

Dr. John Cush RheumNow

1 year 8 months ago
Treat-to-Target Improves Fertility in Women with RA Dr. Richard Conway discusses abstract 1647, presented at #ACR24 https://t.co/vC0CA0lN4M https://t.co/Dfo7iBYwcU
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis

Glucagon-like peptide-1 receptor agonists (GLP

Dr. John Cush RheumNow

1 year 8 months ago
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24 https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii
ORAL Surveillance - Is Statin Use the Problem/Solution?

The findings from ORAL Surveillance Study have been a dominant

Dr. John Cush RheumNow

1 year 8 months ago
ORAL Surveillance - Is Statin Use the Problem/Solution? The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate. https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd
Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate
#ACR24: What Exactly do JAKs and TYKs Do?

Let me start by confessing something embarrassing: the immune system is just

Dr. John Cush RheumNow

1 year 8 months ago
#ACR24: What Exactly do JAKs and TYKs Do? Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD
Addressing CV Risk in RA: Are we doing enough?

The increased risk of cardiovascular disease in patients with rheumatoi

Dr. John Cush RheumNow

1 year 8 months ago
Addressing CV Risk in RA: Are we doing enough? The increased risk of cardiovascular disease in patients with rheumatoid arthritis has long been known (1). #ACR24 https://t.co/dajYuK8rpd https://t.co/2Ds3OZEjUX
Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and
Apremilast Benefits and Risks in PsA

Dr. Akhil Sood discusses abstracts 1466, 2583, 0598 and 2640 discussing the use o

Dr. John Cush RheumNow

1 year 8 months ago
Apremilast Benefits and Risks in PsA Dr. Akhil Sood discusses abstracts 1466, 2583, 0598 and 2640 discussing the use of apremilast in PsA, presented at #ACR24. https://t.co/SSEeR9Xt9B https://t.co/cUeSUQoRsO
#ACR24 BEST Abstracts from Day 2

Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as

Dr. John Cush RheumNow

1 year 8 months ago
#ACR24 BEST Abstracts from Day 2 Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty. https://t.co/9qiPhemEPl https://t.co/uGQEiCcfah
×